Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial

John C. Araujo, Géralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod B. Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goebell, Axel Heidenreich, Johann S. de Bono, Stephen Begbie, Jun H. Hong, Eduardo RichardetEnrique Gallardo, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher J. Logothetis

Research output: Contribution to journalArticlepeer-review

196 Scopus citations

Fingerprint

Dive into the research topics of 'Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences